Sheep Request for Baker Ruskinn SCI-tive Hypoxia Workstation

我们正在通过研究下的共享设备评估计划(SEEP)申请资金 研究和发展办公室为收购面包师而提供的设备管理计划 俄斯金双不对称低氧工作站。该工作站支持体外实验 精确控制氧气浓度，范围从0.1%(缺氧)到20.9%(环境)，增量为0.1%。这 允许研究人员在不同组织类型的生理相关条件下培养细胞。 此外，该工作站还可用于建立缺氧(低氧)或缺氧(无氧)的体外模型 在各种组织类型中。这对于研究心脏病、中风和肢体缺血至关重要，所有这些疾病都会影响 经验丰富的病人群体。我们要求一台双工作站，这将使我们能够维护两台 同时独立控制大气层。每个工作站环境都足够大，可以在其中工作 舒适，以便整个实验可以在受控环境中进行而不受影响 通过暂时暴露在室内空气中。该系统还包括一个倒置显微镜，用于在 这些受控条件不会从受控环境中移除。目前，这项技术是 明尼阿波利斯VAHCS没有提供，我们的设施也没有任何其他具有同等功能的设备 能力。所要求的设备将存放在 明尼阿波利斯VAHCS研究部位于医院主楼内，将向退伍军人事务部提供 调查员作为共同的服务设备。所请求的低氧工作站将补充现有的 基于多用户的工具清单，最终目标是提高效率和资源，同时促进 转化性(从桌面到床边)研究。爱德华·麦克福尔斯博士将监督培训和使用 在明尼阿波利斯VAHCS主任(达尔文·古德斯比德先生)的全力支持下的设备和研究与 发展委员会主席(罗纳德·巴赫博士)。主要用户组和次要用户组对此感兴趣的领域 设备跨越多个退伍军人管理局研究学科，共同代表基础研究和转化性研究 在老龄化、心血管疾病、癌症、神经科学、干细胞疗法、海湾战争疾病以及 肥胖。已确定的退伍军人管理局资助的主要用户将至少占仪器容量的75%。《未成年人》 用户组将占用仪器容量的25%或更少。如果明尼阿波利斯VAHCS仍然是 作为退伍军人管理局系统中规模最大、最活跃的研究计划，我们的调查人员获得访问权限至关重要 到代表该领域黄金标准的高质量、坚固的乐器。《华尔街日报》的收购 低氧工作站将加速和提高来自多个学科的研究人员 获取、分析、显示和理解数据，以造福独特的医疗保健为长期目标 美国退伍军人的需求。我们相信，收购这台设备将增强和扩大临床 我们设施中正在进行的调查的相关性，并将产生新的合作努力，以开发 与退伍军人和普通公众的保健需求有关的疾病的治疗或治疗。

We are requesting funds through the Shared Equipment Evaluation Program (ShEEP) under the Research Equipment Management program offered by the Office of Research and Development to acquire a Baker Ruskinn SCI-tive Dual Asymmetrical Hypoxia Workstation. This workstation supports in vitro experiments with precise control of oxygen concentration ranging from 0.1% (anoxia) to 20.9% (ambient) in 0.1% increments. This allows researchers to grow cells in physiologically relevant conditions, which differ between tissue types. Additionally, this workstation can be used to create in vitro models of hypoxia (low oxygen) or anoxia (no oxygen) in various tissue types. This is critical for the study of heart disease, stroke, and limb ischemia, all of which affect the Veteran patient population. We are requesting a dual workstation, which will allow us to maintain two independently controlled atmospheres simultaneously. Each workstation environment is large enough to work in comfortably, so that entire experiments can be conducted in the controlled environment without being influenced by temporary exposure to room air. This system also includes an inverted microscope to monitor cells under these controlled conditions without removing them from the controlled environment. Currently, this technology is not available at the Minneapolis VAHCS, nor does our facility have any other equipment with equivalent capabilities. The requested equipment will be housed in a shared dedicated instrument room within the Minneapolis VAHCS Research Wing within the main hospital building, and will be made available to VA investigators as common service equipment. The requested hypoxia workstation will compliment an existing inventory of multiuser based instruments with the end goal of increasing efficiency and resources while fostering translational (bench-top to bed-side) research. Dr. Edward McFalls will oversee the training and usage of the equipment under the full support of Minneapolis VAHCS Director (Mr. Darwin Goodspeed) and the Research & Development Committee Chair (Dr. Ronald Bach). The fields of interest of major and minor user groups for this equipment span multiple VA research disciplines, and collectively represent both basic and translational research in areas such as aging, cardiovascular disease, cancer, neuroscience, stem cell therapies, Gulf War Illness, and obesity. The identified VA funded major users will account for at least 75% of the instrument capacity. The minor users group will occupy 25% or less of the instrument capacity. If the Minneapolis VAHCS is to remain one of the largest and most active research programs in the VA system, it is critical for our investigators to gain access to high-quality, robust instruments that represent the gold-standard in the field. The acquisition of the SCI-tive Hypoxia Workstation would accelerate and enhance the rate in which researchers from multiple disciplines can acquire, analyze, display, and understand data, with the long-term goal of benefiting the unique health care needs of US Veterans. We are confident that acquisition of this equipment will enhance and extend the clinical relevance of ongoing investigations in our facility and will generate new collaborative efforts to develop treatments or therapies for diseases relevant to the health care needs of Veterans and to the general public.